Abstract
INTRODUCTION
Pancreatic cancer is a challenging disease with significant morbidity and mortality [1, 2] . In recent years, the incidence worldwide has increased up to 13/100000 per year due to developments in the detection and management of pancreatic cancer [3] . However, only approximately 4% of patients will live 5 years after diagnosis, and the incidence almost approaches mortality [4, 5] . Curative resection is considered the only potential for cure in pancreatic cancer, which can provide prolonged survival; however, even after surgery, the 5-year overall survival rate remains low. Therefore, an accurate staging of the tumor and appropriate treatment strategy is necessary.
The tumor (T), lymph nodes (N), and metastases (M) categories make up the cornerstone of various cancer staging systems of the American Joint Committee on Cancer (AJCC) [6] . In the 6 th and 7 th edition of the AJCC system, stage Ⅲ pancreatic cancer is only defined as T4/ any N/M0, i.e., the tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor) no matter the N stage [7] . In contrast, the 8 th edition defines T4 and N2 categories as two key parameters of Stage Ⅲ, which especially highlights the importance of regional lymph nodes. When there is no distant metastasis, tumors with metastasis in ≥ 4 regional lymph nodes, whatever the T category, is also defined as stage Ⅲ [8] . Clinically, the accurate stage of the pancreatic tumor determines the type of surgical resection, which seriously impacts the patient outcome. Therefore, the aim of this study was to evaluate the changes in the AJCC system for defining stage Ⅲ pancreatic cancer and to identify their prognostic factors. 
MATERIALS AND METHODS

Patients
Statistical analysis
The enrolled patients were divided into three groups based on parameters according to the 8 th edition AJCC criteria [T(1-3)N2; T4N(0-1); T4N2]. Survival curves for overall survival (OS) and disease-specific survival (DSS) were plotted by Kaplan-Meier analysis according to cancer stages. Univariate analysis with the Cox proportional hazards regression model was performed to explore the difference in prognostic factors between the three groups. All statistical analyses were performed using SPSS, version 20 (Armonk, NY, United States). A two-sided P-value of < 0.05 was considered statistically significant.
RESULTS
A total of 1744 pancreatic cancer patients were selected from the SEER database. In contrast, little difference was observed in the prognostic impact on DSS for the AJCC 8 th edition stage Ⅲ system. As shown in Table 3 , there was no significant difference in DSS for Stage T4N(0-1) patients with different marital statuses. In addition, OS and DSS analysis for stage Ⅲ disease stratified by three groups are presented in Figure 1 and 
DISCUSSION
Pancreatic cancer is one of the most lethal human cancers, making its staging clinically significant. By ana lyzing a nationally representative data set, this study further underlines the prognostic relevance of the number of metastatic lymph nodes (N2 vs N1), which allows for a finer stratification of patients in the case of resectable (T1-3) and unresectable (T4) pancreatic cancer. This finding could possibly have relevant repercussions on treatment strategies.
As an aggressive and devastating disease, less than 20% of patients present with localized, potentially curable tumors [2] . In other words, the majority of pancreatic cancers are highly invasive. The most noteworthy finding in the study is that there was no significant difference for OS or DSS between stage T(1-3)N2 and stage T4N(0-1), while they were significantly better than stage T4N2. This indicates that stage Ⅲ is a heterogeneous group and should be subclassified into stage ⅢA [T(1-3)N2/ T4N(0-1)] and stage ⅢB (T4N2).
The AJCC TNM classification is based on the assess ment of resectability [2] . Accordingly, pancreatic cancer is staged. As the basis of cancer staging, tumor size is one of the strongest prognostic factors in pancreatic cancer. T1, T2, and T3 tumors are potentially resectable, whereas T4 tumors are unresectable because they involve the celiac axis or the superior mesenteric artery. In this study, patients undergoing surgical treatment were analyzed to ascertain the prognostic role of the T4 category. In addition, tumor metastasis to regional lymph nodes is a vital step in the progression of cancer [9] . The detection of tumor cells in the lymph nodes is an indication of the spread of the tumor, where some molecules, such as VEGF-C/D and VEGF-R3, play crucial roles as novel key regulators in lymphangiogenesis [10] . There is no doubt that tumor size and lymph node metastases are the two most significant prognostic factors for pancreatic cancer. Apart from these two factors, poor prognostic factors include a high tumor grade and positive margins of resection [11] . This may be why a higher grading was correlated with a worse prognosis in the T(1-3)N2 and T4N2 groups.
On the other hand, the multistep invasion-metastasis cascade for cancer cells is very complex. First, a cancer cell locally invades the surrounding tissue. During metastatic dissemination, it enters the microvasculature of the blood or lymph systems and then survives and translocates to microvessels of distant tissues. Finally, the cancer cell survives and adapts to the foreign microenvironment of distant tissues and forms a secondary tumor [12] [13] [14] . Therefore, the different OS and DSS curves suggest that tumors are in the different processes of invasion; that is to say, a tumor at stage T4N2 is further along than stage T(1-3)N2/T4N(0-1). More thorough research is needed for the different pancreatic cancer cell populations.
Regrettably, this study is a mere statistical analysis of patients with pancreatic cancer based on the SEER data, and a more intensive study is required. More detailed information is necessary for us to confirm the relationship between stage Ⅲ classification and survival. The 8 th edition American Joint Committee on Cancer (AJCC) TNM staging system for pancreatic cancer has been applied in clinical practice since Jan 1 2018. The definition of stage Ⅲ consists of TanyN2M0 and T4NanyM0. Our study aimed to evaluate the changes in the AJCC TNM system for defining stage Ⅲ pancreatic cancer. The 8 th edition AJCC TNM staging system for pancreatic cancer has just been applied in clinical practice for a short while and has not been validated yet. Hence, we used a population-based database to evaluate the rationality of the new staging system.
ARTICLE HIGHLIGHTS
Research background
Research motivation
Research objectives
The primary purpose of this study was to examine the accuracy of classification of stage Ⅲ. If there was some inadequacy, we would make necessary modifications in order to assure the precise staging.
Research methods
Patients were selected from the Surveillance Epidemiology and End Results database (2004-2013) and were divided into three groups: T(1-3)N2, T4N(0-1), and T4N2. Overall survival (OS) and disease-specific survival (DSS) of each group were evaluated by the Kaplan-Meier method.
Research results
A significant difference was observed in OS and DSS between T(1-3)N2/ T4N(0-1) and T4N2 but not between T(1-3)N2 and T4N(0-1), which indicated stage Ⅲ was a heterogeneous group. Additionally, a higher grading correlated with a worse prognosis in the T(1-3)N2 and T4N2 groups.
Research conclusions
Patients with stage T4N2 had a worse prognosis than those with stage T(1-3)N2/T4N(0-1) in the 8 th edition AJCC staging system for pancreatic cancer. 
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